Urokinase Like Plasminogen Activator Levels in Patients Undergoing Bronchoscopy

Completed

Conditions studied: Hemoptysis

In brief

Some of the risk factors for bleeding following bronchoscopy is having a malignancy or an immunocompromised state. The etiology of this remains uncertain. The investigators suspect that individuals with malignancy have abnormalities involving certain factors that influence the coagulation pathway. The investigators plan to measure these factors prior to and after bronchoscopy.

Key facts

Study ID

NCT00929565

Run by

University of Oklahoma

People needed

10

Starts

2009-06-01

Expected to finish

2011-10-01

Last updated by the study team

2012-04-09

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Any patient scheduled to undergo bronchoscopy

You may not qualify if…

• Patients with evidence of coagulopathy either iatrogenic or the result of disease process - coagulopathy defined as elevated prothrombin time, activated partial thromboplastin time or platelet count less than 100,000
• Patients not scheduled to undergo bronchoalveolar lavage (BAL)

Where it is running

• VA Medical Center — Oklahoma City, Oklahoma, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.